2024 Poster Presentations Coming in August


Here is a reminder of the posters presented in 2023.

POSTER SESSION A:  Monday-Tuesday 

A01: Synthetic Enzymatically Produced DNA for Gene Therapy and Vaccine Applications, Presented by Heikki L., 4basebio UK Ltd.

A02: Production of In Vitro Transcribed mRNA Using Synthetic, Enzymatically Produced Linear DNA, Presented by Amy W., 4basebio UK Ltd.

A03: Solubility Screening of Biologic Drug Candidates Using a Miniaturized Polyethylene Glycol (PEG) Precipitation Assay, Presented by Chen Z., AbbVie

A04: Simplify Process Development for Intensive Cell Culture with Biogenstar's Fully Integrated Perfusion Bioreactor, Presented by Yu L., ALIT LifeTech, Inc.

A05: Accelerating Process Development of iPSC-Derived Natural Killer Cell Therapies with Fully Integrated Perfusion Cell Culture Devices, Presented by Yi Z., ALIT LifeTech, Inc.

A06: Detection and Biophysical Characterization of Distinct Empty Capsid Populations in AAV Preparations, Presented by Surya A., BioMarin Pharmaceutical, Inc.

A07: Rapid Purity and Charge Heterogeneity Analysis of Anti-CD4 mAb Culture Variants by Maurice™, Presented by Anna A., Bio-Techne

A08: An Automated Immunoassay Platform for Rapid and Sensitive Quantitation of AAV Capsids in Bioprocess Samples, Presented by Yoav N., Bio-Techne

A09: Characterization of Oxygen Mass Transfer Rate (kLa) Using a Statistical Design of Experiment (DoE) for Bioreactor Scale-Up, Presented by Don O., Boston Institute of Biotechnology

A10: Optimization of an AAV Infectious Titer Method for Two rAAV Vectors, Presented by Thomas H., Bristol Myers Squibb

A11: Development of Real-Time Automated In-process Data Monitoring and Predictive Models, Presented by Qing M., Bristol Myers Squibb

A12: High Throughput Feed Media Screening for Trace Metal Impact to Titer Variability, Presented by Karina R., Bristol Myers Squibb

A13: Optimizing Washing Efficiency in Cell Washing and Media Exchange for Cell Therapy Manufacturing, Presented by Robert R., CARR Biosystems

A14: Analyzing the Bio-Separation of Chinese Hamster Ovary-S (CHO-S) Cells, Presented by Robert R., CARR Biosystems

A15: Cell Harvesting: Optimizing Viability and Recovery in Cell Therapy, Presented by Robert R., CARR Biosystems

A16: Engineering Multiple Phenotypes into CHO and HEK-293 Cells to Increase mAb Productivity and AAV Productivity, Respectively, Presented by Larry F., CHO Plus, Inc.

A17: Utilizing Retrovirus-Like Particles (RVLP) to Evaluate Viral Clearance for Multiple Modes of Separation, Presented by David C., Cygnus Technologies, LLC

A18: An Optimized and Validated Workflow for Developing Stable Producer Cell Lines with >99.99% Assurance of Clonality and High Clone Recovery, Presented by John C., CYTENA

A19: Quantitation of AAV Ratios in a Dual-Vector System Using SV-AUC, Presented by Carlo C., Decibel Therapeutics

A20: Filamentous Fungal Cell Cultures Bloom with Benefits for Manufacturers and Patients Globally, Presented by Mark E., Dyadic International, Inc.

A21: An Automated Data Analysis Workflow for Accelerating Confident Detection of Low-Abundance HCPs, Presented by Amy C., Genedata AG

A22: Developing RNA Therapeutics with the Genedata Biopharma Platform, Presented by Yi-Wei L., Genedata, Inc.

A23: NGS-Driven Critical Quality Attribute Assessment of Biologically Synthetized mRNA Therapeutic Products, Presented by Ivan S., Genedata, Inc.

A24: Establishment of a LC-MS/MS Workflow for In-Depth and Comprehensive HCP Characterization, Presented by Li C., GlaxoSmithKline

A25: Characterize mAb Stability from Cell Line Development Through Product Release with Aura, Presented by Andrew S., Halo Labs

A26: Electric Field-Assisted Membrane System for Nanoparticle Separation and Preconcentration, Presented by Kwanoh K., Korea Institute of Machinery and Materials

A27: Laser Force Cytology Advanced Analytics Are Transforming Viral Vector, Vaccine and Cell Therapy Process Development and Manufacturing, Enabling Higher Product Consistency and Yields, Presented by Colin H., LumaCyte

A28: Real-Time Online Monitoring of Yeast Cell Growth in the Shake-Flask, Presented by Jean-Francois H., Massachusetts Institute of Technology

A29: Bioprocess Development: Use of Multimodal Chromatography to Remove Key Host Cell Protein in the Purification of Live Virus Vaccines, Presented by Devan R., Merch & Co., Inc.

A30: Potential Benefits of Dextran Sulfate for Suspension Cell Growth and Virus Production, Presented by Rebecca H., Merck & Co., Inc.

A31: Progress on a Sub-Micrometer Particle Number Concentration Reference Material, Presented by Kurt B., National Institute of Standards and Technology

A32: Advanced Gradient SMB Applied to Oligonucleotides Purification, Presented by Masahiro O., Organo Corporation

A33: HaLCon, a Fit-for-Purpose, Platform Method for Rapid Antibody Concentration Measurements from Cell-Free Culture Media, Presented by Richard H., RedShift Bio

A34: Disruptive Technologies Transforming Upstream Process Intensification for All Modalities, Presented by Charles H., Repligen

A35: The Next Generation of XCell® ATF Controllers for High Cell Density Perfusion Cell Culture, Presented by Melisa C., Repligen

A36: High-Throughput Method to Analyze the Cytotoxicity of CAR T Cells in a 3D Tumor Spheroid Model Using Celigo® Image Cytometer, Presented by Leo C., Revvity

A37: Improved Inter-Instrument Consistency and High Precision for CHO Cell Bioprocessing Using the Cellaca® MX High-Throughput Cell Counter, Presented by Bo L., Revvity

A38: A Faster Sensitive CHO HCP Impurity Quantification Workflow - AlphaLISA® & HTRF®, Presented by Jillian M., Revvity

A39: Development of Anti-Host Cell Protein Antibodies and Reagent Qualification Using Orthogonal Analytical Methods, Presented by Dan K., Rockland Immunochemicals, Inc.

A40: Challenges and Mitigations in Designing and Executing In-Use Compatibility Studies to Support a Global Gene Therapy Clinical Trial, Presented by Sheetal D., Sangamo Therapeutics

A41: A Combined Inducible Mammalian Expression System and Novel Affinity Tag Provides a Powerful Tool for the Productivity of Difficult-to-Express Proteins, Presented by Megan B., Sanofi

A42: Novel Bioassays in Picodroplets – Accelerating Biotherapeutics Discovery and Development, Presented by Frank C., Sphere Fluidics

A43: Detecting and Characterizing Free Fatty Acids with Holographic Particle Characterization, Presented by Laura P., Spheryx, Inc.

A44: A TaqMan-Based PCR Multiplex Mycoplasma Detection Assay for Rapid Lot-Release Testing in Cell Therapeutics, Presented by Kathleen D., Thermo Fisher Scientific

A45: Design of Continuous Perfusion Systems for Biologics Production from Suspension and Adherent Cells, Presented by Je-Nie P., U.S. Food and Drug Administration

A46: Process Optimization in HEK293 Improves rAAV Full Capsid Percentage and Relative Potency, Presented by Kostantinos K., Ultragenyx Pharmaceutical, Inc.

A47: Low-Residence-Time Affinity Chromatography Enables Cost of Good Reduction of Recombinant Adeno-Associated Virus Purification Process, Presented by Hanson Z., Ultragenyx Pharmaceutical, Inc.

A48: Intensified Viral Manufacturing Using an Automated, High-Cell Density Platform Supporting Continuous Processing, Presented by David M., UNIVERCELLS Technology

A49: Protein Unfolding and Aggregation Under Hydrodynamic Flow, Presented by Alexander P., University of Leeds

A50: Rapid HEK Platform Scale Up to 200 L Using kLa Modeling, Presented by Christian G., Voyager Therapeutics

A51: Rapid CIP Using Membrane-Based GORE® Protein Capture Devices with Protein A, Presented by Jeffrey C., W. L. Gore & Associates, Inc.

A52: Identification of Specific-Neutralizing Antibodies for Highly Pathogenic Avian Influenza H5 Clades Reveals Future Vaccine Designs and Therapeutics, Presented by Hyun P., Wonkwang University

A53: Characterizing Protein Aggregation Using Flow Imaging Microscopy with Orthogonal and Complementary Analytical Techniques, Presented by Austin D., Yokogawa Fluid Imaging Technologies, Inc.

A54: Development of Serum-Free Chemically-Defined Cryopreservation Media for Mammalian Cells (CHO and HEK293) Without DMSO and Animal Derived Components, Presented by Duk Jae O., Sejong University

POSTER SESSION B:  Wednesday-Thursday 

B01: Production of AAV Vectors Using Synthetic, Enzymatically Produced Linear DNA, Presented by Florent F., 4basebio UK Ltd.

B02: Know Your Process: On-Line and At-Line Analytics for Upstream Bioprocess Key Nutrients, Presented by Michael C., 908 Devices, Inc.

B03: Simple-Efficient Microchip CE-MS Workflows to Characterize Biotherapeutics: From mAbs, to Nucleic Acids, to AAVs, Presented by Aditya K., 908 Devices, Inc.

B04: Buffer Concentrates for Biotherapeutic Pilot Economization, Presented by Philip H., Alexion Pharmaceuticals

B05: Comparability Strategy and Demonstration for Post-Approval Production Cell Line Change of a Bevacizumab Biosimilar IBI305, Presented by Kenneth M., Altruist Biotechnology Suzhou Co. Ltd.

B06: Enabling State-of-the-Art Process Technologies, Presented by Kenneth M., Altruist Biotechnology Suzhou Co. Ltd.

B07: An Accelerated Approach to the Development of a 2nd Generation Downstream Process, Presented by Leticia M., APC Ltd.

B08: High-Throughput Purification Workflow to Streamline Early Drug Discovery, Presented by John H., BioMarin Pharmaceutical, Inc.

B09: Flexible Alternatives to Process Intensification for mAb Purification, Presented by Walter E., Bio-Rad Laboratories

B10: Chromatography Purification of AAV8 Using Mixed-Mode Chromatography, Presented by Khaled M., Bio-Rad Laboratories

B11: Purification of Single-Stranded Oligonucleotides Using Anion Exchange Chromatography, Presented by William R., Bio-Rad Laboratories

B12: The TcBuster Advantage: Using Non-Viral Transposase System for Highly Efficient and Robust Delivery of Multicistronic Therapeutic Cargo in Immune Cells, Presented by Hallie H., Bio-Techne

B13: A Tale of Two Process Analytical Technologies: Increasing Process Robustness with FlowVPX and Patrol, Presented by Timothy B., Bristol Myers Squibb

B14: Impact of Poloxamer 188 Material Attributes on Proteinaceous Visible Particle Formation in Liquid Monoclonal Antibody Formulations, Presented by Kohei S., Chugai Pharmaceutical Co., Ltd.

B15: Sustainable Compendial Grade GMP Detergent Substitutes for Triton™ X-100 in Bioprocessing Applications, Presented by Garima S., Croda, Inc.

B16: Bench Scale to Clinical Trial Manufacturing: Overcoming Challenges in Scaling Up an mRNA Lipid Nanoparticle Vaccine, Presented by Nick M., CSL Seqirus

B17: Development and Optimization of a Scalable Affinity Purification of Adeno Associated Virus Serotype 6, Presented by Azam H., ElevateBio

B18: Evaluation of Cytiva Wand Single Use Mixing Technology for High Viscosity Drug Product Formulations, Presented by Paula AR., Eli Lilly and Company

B19: AAV9 In Vitro Potency Loss During Downstream Chromatography Purification Steps – Potential Causes and Mechanisms, Presented by Hsuan-Ni L., Eli Lilly and Company

B20: Peptides-Based-Solutions to Reduce Undesired Cell Culture Media Chemistry: New Options for Stabilized Media Formulations, Presented by Manish R., Evonik Operations GmbH

B21: Performance of BSA Filtration Using Sterilizing Grade PVDF and PVDF/PES Hybrid Membranes, Presented by Stephanie L., Fujifilm Diosynth Biotechnologies

B22: Evaluating the Versatility of Gator® Next Generation BLI Platform for Biotherapeutic Development and Gene Therapy, Presented by Vasundhra B., Gator Bio

B23: Enhancing New Peak Detection (NPD) in the Multi-Attribute Method (MAM) Through a Streamlined Data Analysis Workflow, Presented by Christian L., Genedata AG

B24: NGS-Based Quality and Safety Control for Cell and Gene Therapy Products, Presented by David K., Genedata, Inc.

B25: Determination of Viral Titer and Host Cell Proteins to Support Viral Vector Production in Gene Therapy Using an Automated, Miniaturized Immunoassay, Presented by Ellen L., Gyros Protein Technologies

B26: Accelerating Bioprocess Workflows with Microfluidic Immunoassay-Based Parallel Impurity Analysis, Presented by Ellen L., Gyros Protein Technologies

B27: Shortening the Pipeline from Customer into Clinics: Development of a Downstream Processing Platform for Adeno-Associated Virus (AAV), Presented by Jule G., IDT Biologika GmbH

B28: Enabling High Concentration IgM Drug Products: New Territory and Platform Development, Presented by Daniel K., IGM Biosciences, Inc.

B29: Nebulized IGM: Importance of Buffering System and Surfactant to Prevent Aggregation and Enable Inhalation Delivery, Presented by Sameer S., IGM Biosciences, Inc.

B30: A Mathematical Approach to Bridge Metabolic Parameters to CAR T Cell Growth in Limited Data Conditions, Presented by Keshav P., Janssen Pharmaceuticals

B31: From Screening to Scale-Up: Optimization on mAb Purification Using Protein A Membrane Chromatography, Presented by Melissa K., Kemp Proteins

B32: Rapid Microfluidic Automated Contaminant Detection by Multiplexed Real Time-qPCR, Presented by Jessica H., Lonza Biologics, Inc.

B33: Optimizing Retroviral Process Scale-Up to Enable Clinical Manufacturing of CAR-T Cell Therapies Using the Automated Cocoon® Platform, Presented by Kathleen Z., Lonza Personalized Medicine

B34: Mixing Scale-Up of Biologics Formulations in the Drug Product Manufacturing Process, Presented by Robert K., Merck & Co., Inc.

B35: Evaluation of Hydrophobic Interaction, Hydroxyapatite, and Mixed Mode Chromatography for Separation of dsRNA in an mRNA Vaccine Purification Process, Presented by Christopher W., Merck & Co., Inc.

B36: Scale Up of cGMP Lipid Polymer Nanocomplexes (LPNC's) for AAV Manufacturing, from Flask to Benchtop Bioreactor, Presented by Geddy H., Mirus Bio LLC

B37: Drydux: An Implantable Technology for Rapid, Inexpensive, and Potent CAR T Cell Therapy, Presented by Micah M., North Carolina State University

B38: Scalable Production of Induced Pluripotent Stem Cell-Derived CD8+ CAR-T Cells in Stirred Tank Reactors Using DLL4/VCAM-1 Coated Beads, Presented by Vaisakh R., Notch Therapeutics

B39: Revolutionary Variable Pathlength Spectroscopy for AAV Titer Determination to Accelerate Processes Development, Presented by Yan C., PTC Therapeutics, Inc.

B40: Evaluate of Full and Empty AAV Separation Between Strong and Weak Anion Exchange Ligands on Resin and Monolith Column Formats, Presented by Kevin S., PTC Therapeutics, Inc.

B41: Developing an Improved Affinity Chromatography Process for Adeno-Associated Virus, Serotype 5 (AAV5), Presented by Laura P., Repligen

B42: A Rapid and High-Throughput T Cell Immunophenotyping Assay for Cellular Therapy Bioprocess Using the Cellaca® PLX Image Cytometer, Presented by Carolina FN., Revvity

B43: AlphaLISA® Adeno Associated Virus (AAV) Kits – A Faster and More Sensitive AAV Capsid Detection Method, Presented by Jillian M., Revvity

B44: Environment Social Governance Solution for Fluorescence-Labeled ssDNA Fragment Analysis Using Denature Microfluidics Capillary Electrophoresis, an Application for CRISPR Enzyme Study and RNA Capping Study, Presented by Yanhong T., Revvity

B45: Optimization of AAV Sample Preparation Towards Accurate Quantification of Viral Titer by dPCR, Presented by Zoe B., Teknova

B46: A Novel Cell-Based AAV RNA-Sensing Infectivity Reporter Assay, Presented by Michel C., Teknova

B47: Optimized AEX Buffer Formulations for AAV Full Capsid Enrichment, Presented by Michel C., Teknova

B48: Two qPCR Based Assays to Quantitate Total Lentiviral Particles and Proviral Copy Number for Viral Vector Characterization, Presented by Frank P., Thermo Fisher Scientific

B49: Evaluate Polyethylenimine Clearance in Purification Process of Recombinant Adeno-Associated Viral Vector, Presented by Kyle K., Ultragenyx Pharmaceutical, Inc.

B50: Exploring the Production Potential and Mechanoresponsiveness of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem/Stromal Cells for Extracellular Vesicle Biomanufacturing, Presented by Emily P., University of Maryland

B51: Delivering Consistent Protein A Membrane Scalability: GORE® Protein Capture Devices with Protein A, Presented by Matt I., W. L. Gore & Associates, Inc.

B52: Extended Cycling Durability, High Productivity Membrane-Based Affinity Purification Using GORE® Protein Capture Devices with Protein A, Presented by Eric V., W. L. Gore & Associates, Inc.

B53: Cell Culture Media Monitoring in Cell and Gene Therapy Supporting Upstream Bioprocessing, Presented by Yun A., Waters Corporation

B54: Application of LabChip Empty/Full Microfluidic Assays for AAV2 and AAV9 Analysis, Presented by Menel B., Revvity